All sponsors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS54
PHASE 3 / 2-326
RECRUITING38
READOUTS ≤12 MONTHS12
READOUT SLIPPED >6 MO19%

Delay Index: of 32 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Suzhou Suncadia Biopharmaceuticals Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SHR-1701、CAPOX
NCT04950322
P3Active, not recruitingGastric or Gastroesophageal Junction Cancer7372024-05-20
NCT07028268
NCT07028268
P2RecruitingFor Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors2102025-12
SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
NCT06247956
P2Active, not recruitingAdvanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma1532025-12-30 (+11 mo)
SHR-1826
NCT06703177
P1/2RecruitingAdvanced Solid Tumors8762026-01-01
SHR-A1811
NCT06199973
P3Active, not recruitingAdvanced Colorectal Cancer1302026-04
SHR-A1921
NCT06394492
P3RecruitingOvarian Cancer4402026-05-31
SHR-1314 injection
NCT06640257
P3Active, not recruitingPsoriatic Arthritis2082026-06-05 (+1 mo)
SHR-1314
NCT06833307
P3Not yet recruitingChildren and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis902026-07
Adebrelimab Injection
NCT07110571
P2RecruitingGastric Cancer; Gastroesophageal-junction Cancer2002026-08
SHR-A1811
NCT06859775
P1/2RecruitingRecurrent or Metastatic Cervical Cancer1002026-10
SHR-8068
NCT06618664
P3RecruitingAdvanced Hepatocellular Carcinoma5902026-10 (+6 mo)
SHR-1681
NCT06737731
P1/2RecruitingMalignant Solid Tumors3002026-11
SHR-A2009 monotherapy
NCT06671379
P3Active, not recruitingNon-small Cell Lung Cancer4982026-12
SHR-1826;Adebrelimab;SHR-8068;Bevacizumab
NCT06844474
P2RecruitingNSCLC3002026-12 (+3 mo)
SHR-A1811
NCT06840002
P1/2RecruitingOvarian Cancer1502026-12 (+7 mo)
SHR-8068
NCT06465563
P2Active, not recruitingBiliary Tract Cancer932026-12-30
SHR-4375 Injection
NCT07298772
P1/2RecruitingAdvanced Solid Tumor1982027-01
SHR-A1912 Injection
NCT06929624
P3Active, not recruitingDiffuse Large B-cell Lymphoma2822027-03
SHR-A2102
NCT07059221
P1/2RecruitingRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma2102027-03 (+12 mo)
SHR-9839(sc) For Injection
NCT07229638
P1/2RecruitingSolid Tumor702027-04 (-14 mo)
SHR-4375
NCT06764628
P1/2RecruitingSolid Tumors2082027-05
SHR-8068 Injection
NCT07682272
P2Not yet recruitingResectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk1202027-07
Almonertinib combined with SHR-1701
NCT05503888
P1/2Not yet recruitingRelapsed or Advanced Non-small Cell Lung Cancer1602027-07-30
SHR-9839(sc) for Injection
NCT07751341
P2RecruitingAdvanced Esophageal Squamous Cell Carcinoma842027-12
SHR-A2102 for Injection
NCT07418749
P3RecruitingRecurrent Cervical Cancer; Metastatic Cervical Cancer3982027-12
SHR-1826
NCT06754930
P1/2RecruitingNon-small Cell Lung Cancer (NSCLC)4002027-12
SHR-A1811 and SHR-1701
NCT05671822
P2RecruitingHER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma2582027-12 (+16 mo)
SHR-3276
NCT06643754
P1/2RecruitingAdvanced Solid Tumors1152027-12-30
SHR-A2102 and Adebrelimab
NCT07393542
P3RecruitingLocally Advanced or Metastatic Urothelial Carcinoma4532028-01-31
SHR-1314 Injection
NCT06860750
P3RecruitingActive Non-radiographic Axial Spondyloarthritis3802028-02 (+10 mo)
SHR-A1811 for Injection
NCT07111832
P3RecruitingPD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer4002028-03
SHR-A1811
NCT06778031
P2RecruitingHER2-positive Locally Advanced or Metastatic Biliary Tract Cancer542028-06
Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
NCT07704645
P2Not yet recruitingResectable Non-small Cell Lung Cancer1802028-06
SHR-1826
NCT07489716
P2RecruitingNon-Small Cell Lung Cancer902028-08
SHR-4298 Injection
NCT07229612
P1/2RecruitingMalignant Solid Tumors2002028-11
SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
NCT07028281
P2RecruitingMalignant Solid Tumors1202028-12
adebrelimab + SHR-A2009
NCT07863167
P2RecruitingNon-small Cell Lung Cancer6602028-12-30
SHR-A2009 + bevacizumab
NCT07895992
P3Not yet recruitingNon-squamous Non-small Cell Lung Cancer4902028-12-30
SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
NCT07676162
P3RecruitingAdvanced Colorectal Cancer3002029-09
NiBladder 2
NCT07726992
P3RecruitingPapillary-Only Non-muscle-invasive Bladder Cancer7502029-12
SHR-8068 Injection
NCT07229625
P3RecruitingAdvanced Biliary Tract Cancer6042029-12
trastuzumab
NCT07779538
P3RecruitingOvarian Cancer4202030-02-28
SHR-1501 for Injection
NCT07424287
P3RecruitingNMIBC2362030-06
SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection
NCT07118527
P3RecruitingPatients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma6002030-10
SHR-A1904 for Injection
NCT07450976
P2RecruitingBiliary Tract Cancer1512030-12
SHR-8068;Adebrelimab ;Bevacizumab
NCT07239596
P1/2RecruitingAdvanced Renal Cell Carcinoma922030-12
Trastuzumab Rezetecan for Injection
NCT07679360
P3RecruitingTriple Negative Breast Cancer10002030-12
SHR-8068,adebelizumab and platinum-based chemotherapy
NCT07170995
P3RecruitingAdvanced or Metastatic Non-small Cell Lung Cancer4602030-12
SHR-A1811 Injection
NCT07896005
P3Not yet recruitingNon Small Cell Lung Cancer4362031-02
SHR-8068 + Adebrelimab + Bevacizumab
NCT07691762
P3Not yet recruitingHepatocellular Carcinoma6902031-09
SHR-8068 Injection
NCT07071714
P2Active, not recruitingColorectal Cancer1032031-10
SHR-A2102
NCT06879145
P2/3RecruitingMuscular Invasive Bladder Cancer (MIBC)7402031-12
Adebrelimab in combination with SHR-8068 and chemotherapy
NCT07454720
P2/3RecruitingLocally Advanced Resectable Rectal Cancer1652032-11
SHR-A2009 ; Aumolertinib
NCT07183189
P3Active, not recruitingNon-small Cell Lung Cancer5822032-11